Thyroid cancer
Conditions
Interventions
Group 1:Deep muscle relaxation + britine antagonism
Group 2:Moderate muscle relaxation + neospermine antagonism
Sponsors
Fudan University Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 65 years with no gender limitation; 2. ASA grade I or II; 3. Body mass index (BMI) <30kg/m^2; 4. Thyroid cancer patients; 5. Voluntarily participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Known allergy to the main drug or any excipient of the product; 2. The patient did not agree to receive recurrent laryngeal nerve monitoring; 3. Patients receiving medication that affects the effect of neuromuscular blockers; 4. Increased intracranial pressure or head injury; 5. Patients with low blood pressure, asthma (avoid using during the attack), epilepsy, neurological disease or neuromuscular disease; 6. Patients with expected difficult airway; 7. Preoperative liver and kidney function: abnormal alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen (BUN), creatinine (Cr) (ALT and AST were 1.5 times higher than the upper limit of normal, BUN and Cr were higher than the upper limit of normal); 8. Coronary heart disease, bronchial asthma, improperly controlled or difficult to control hypertension: systolic blood pressure (SBP) >=160mmHg or diastolic blood pressure (DBP) >=100mmHg; 9. Respiratory insufficiency and respiratory failure; 10. Patients who cannot express their wishes correctly; Poor compliance, unable to complete the experiment according to the study plan; 11. Participated in other drug trials within 30 days prior to enrollment; 12. Abnormal coagulation function; 13. The investigator did not consider it appropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative sore throat;Swallowing time operation;Postoperative bleeding;The second step;Postoperative nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rocuronium dosage;Visual analogue scale score;Satisfaction;Other adverse events;Sedation scores; | — |
Countries
China
Contacts
Public ContactHou Wenting
Fudan University Cancer Hospital
Outcome results
None listed